Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Postpartum clinical cure study in women with chronic hepatitis B
ChiCTR2400085066Phase 4Recruiting
- Sponsor
- Xixi Hospital of Hangzhou
- Start
- May 2024
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of peginterferon alfa-2b in Chronic Hepatitis B (CHB) (4 arms), sponsored by Xixi Hospital of Hangzhou. Primary endpoint: HBsAg negative conversion rate during treatment and follow-up. Started May 2024; status: recruiting.
02
Drugs
peginterferon alfa-2b
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ChiCTR2400085066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085066.